Relevium Announces Settlement of the Outstanding Notes
June 30 2021 - 10:19AM
Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and
Frankfurt: “6BX”) (the “
Company”
or “
Relevium”), announces today
it has reached an agreement to settle the outstanding notes
totalling $2,798,550.
SETTLEMENT DETAILS OF THE OUTSTANDING
NOTES
On December 20, 2018, the company issued Notes
to the Holders with a principal amount of $2,352,942, which matured
on December 20, 2020, and were subsequently extended until June 1,
2021. As announced on June 10, 2021, the Company began negotiations
to settle the outstanding debt and the Company and the Note Holders
have agreed to settle the total of $2,798,550, including interest
and accrued fees as follows:
- Shares for debt settlement of
$2,434,439 at a price equals to $0.02, reflecting market closing
pricing in accordance with TSXV Exchange policy and pricing relief
extended to issuers due to the pandemic.
- Cash payment for the balance over
the next 60-days totalling $364,111.
The settlement will not create a Control
Person as defined by Canadian Securities Laws.
THIS SETTLEMENT AGREEMENT IS SUBJECT AND
CONDITIONAL TO THE REVIEW AND APPROVAL BY THE TSX VENTURE
EXCHANGE.
TOWNHALL AND CONFERENCE
CALL
The Company will be hosting a TOWNHALL AND
CONFERENCE CALL today at 4:15PM Eastern Time, where we are
pleased to welcome John Kupice, CEO of H-Source Holdings (TSX.V:
HSI).
Please note the details below for the event:
- Date and Time:
Wednesday June 30, 2021, at 4:15PM Eastern Time.
- Registration:
Attendees must register in advance by CLICKING HERE
- Q&A Session:
Please submit your questions to investors@releviumcorp.com using
subject line “Question”
About Relevium
TechnologiesRelevium is a publicly traded Company that
operates in the health and wellness industry, including
cannabinoids, with a primary focus on online distribution. The
principal business of the Company is the identification,
evaluation, acquisition and operation of brands and businesses in
the health and wellness markets and cannabinoids. The Company
pursues its business strategy through an acquisition and
partnership model in a holistic approach to encompass a wide range
of health and wellness consumer products. Relevium operates in
various segments including health, wellness, cannabinoid research
and PPE business.
Neither the
TSX Venture
Exchange nor its
Regulation Services Provider
(as that term
is defined in
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
Cautionary Note Regarding
Forward-Looking StatementsThis release includes certain
statements and information that may constitute forward-looking
information within the meaning of applicable Canadian securities
laws. All statements in this news release, other than statements of
historical facts, including statements regarding future estimates,
plans, objectives, assumptions or expectations of future
performance, including the timing and completion of the proposed
acquisitions, are forward-looking statements and contain
forward-looking information. Generally, forward- looking statements
and information can be identified by the use of forward-looking
terminology such as "intends" or "anticipates", or variations of
such words and phrases or statements that certain actions, events
or results "may", "could", "should", "would" or "occur".
Forward-looking statements are based on certain
material assumptions and analysis made by the Company and the
opinions and estimates of management as of the date of this press
release, including the assumptions that the Company will be able to
apply for and ultimately obtain an ACMPR licence, the proposed
business of Biocannabix will develop as anticipated, that the
Company will raise sufficient funds to develop the Biocannabix
business, and that the Company will obtain all requisite regulatory
approvals.
These forward-looking statements are subject to
known and unknown risks, uncertainties and other factors that may
cause the actual results, level of activity, performance or
achievements of the Company to be materially different from those
expressed or implied by such forward-looking statements or
forward-looking information. Important factors that may cause
actual results to vary, include, without limitation, the risk that
the proposed business developments may not occur as planned; the
timing and receipt of requisite approvals and failure to raise
sufficient funds.
Although management of the Company has attempted
to identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward- looking
statements and forward-looking information. Readers are cautioned
that reliance on such information may not be appropriate for other
purposes. The Company does not undertake to update any
forward-looking statement, forward-looking information or financial
outlook that are incorporated by reference herein, except in
accordance with applicable securities laws. We seek safe
harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES
INC.
Aurelio UsechePresident and CEO
For more information about this press release: Tel:
+1.888.528.8687
RELEVIUM TECHNOLOGIES INCEmail:
investors@releviumcorp.com Website: www.releviumtechnologies.com
Like us on FacebookFollow us on Twitter Follow us on LinkedIn
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Apr 2023 to Apr 2024